More about
Crohn's Disease
News
September 18, 2024
2 min read
Save
Early endoscopic response to Skyrizi induction linked to fewer hospitalizations in Crohn’s
Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations and surgeries through 52 weeks of maintenance in patients with moderately to severely active disease, research showed.
News
September 09, 2024
2 min read
Save
Early biological therapy for Crohn’s boosts transmural healing threefold, improves outcomes
Initiation of biological therapy within the first year of Crohn’s disease diagnosis was associated with a higher rate of transmural healing, as well as decreased risk for bowel damage progression, surgery and therapy escalation.
Clinical Guidance
Ulcerative Colitis
Assessment and Treatment
Aminosalicylate Therapy
Clinical Guidance
Ulcerative Colitis
Presentation and Diagnosis
Diagnosis and Evaluation
Clinical Guidance
Ulcerative Colitis
Presentation and Diagnosis
Clinical Presentation
Clinical Guidance
Ulcerative Colitis
Overview
Environmental Risk and Protective Factors
Clinical Guidance
Ulcerative Colitis
Overview
Etiopathogenesis
Clinical Guidance
Ulcerative Colitis
Overview
Epidemiology
News
August 12, 2024
2 min read
Save
Skyrizi outperforms Stelara in endoscopic remission at week 48 in Crohn’s disease
Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.
Clinical Guidance
Ankylosing Spondylitis
Overview